Global Cancer Monoclonal Antibodies Market Size, Forecasts, And Opportunities – Includes Cancer Monoclonal Antibodies Market Share
Learn about the global cancer monoclonal antibodies market through The Business Research Company, which provides information on cancer monoclonal antibodies market size, cancer monoclonal antibodies market drivers and restraints, cancer monoclonal antibodies market players, the COVID-19 impact on the cancer monoclonal antibodies market, and more.
The cancer monoclonal antibodies market size is expected to grow from $53.78 billion in 2020 to $86.05 billion in 2025 at a rate of 9.9%. The global cancer monoclonal antibodies market size is then expected to grow at a CAGR of 7.3% from 2025 and reach $122.28 billion in 2030.
The rising prevalence of cancer cases across the globe is likely to contribute to the growth of the cancer monoclonal antibody market during the forecast period.
Request A Sample For The Global Cancer Monoclonal Antibodies Market Report:
The cancer monoclonal antibodies market consists of sales of cancer monoclonal antibodies and related services by entities (organizations, sole traders and partnerships) that produce cancer monoclonal antibodies that prevent or inhibit the proliferation, maturation or survival of cancer cells. Cancer monoclonal antibodies recognize and bind to proteins in a highly selective manner. By binding specifically to proteins expressed by cancer cells they can selectively target these transformed cells and destroy them by activating the immune response or delivering cytotoxins.
Global Cancer Monoclonal Antibodies Market Segments Include:
By Monoclonal Antibody Therapies: Avastin, Herceptin, Keytruda, Opdivo, Darzalex, Perjeta, Others
By Application: Breast Cancer, Blood Cancer, Liver Cancer, Brain Cancer, Colorectal Cancer, Others
By End-User: Hospitals and Clinics, Research Laboratories, Pharmacies, Others
By Geography: The market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa. Among these regions, North America was the largest region in the cancer monoclonal antibodies market, accounting for 47.9% of the total in 2021.
Humanized antibodies are the antibodies derived from non-human species whose proteins have been modified to enhance their resemblance to natural human antibodies. The humanized antibodies can be generated through recombinant DNA methods using an appropriate vector and expression in mammalian cells. The humanized antibody has advantages such as reduced immunogenicity, and increased serum half-life of the mAb in humans. The first fully human therapeutic antibody, adalimumab (Humira), an anti-tumor necrosis factor a (TNFa) human antibody was approved in 2002 by the US FDA for rheumatoid arthritis.
Major Market Players: F. Hoffmann-La Roche Ltd, Merck & Co., Inc, Bristol Myers Squibb Company, Johnson & Johnson, Amgen Inc.
Regions: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
Countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
Time Series: Five years historic (2016-21) and ten years forecast (2022-2026-2031)
The Cancer Monoclonal Antibodies Market Report 2022 is one of a series of new reports from The Business Research Company that provides cancer monoclonal antibodies market overviews, analyzes and forecasts market size, share, cancer monoclonal antibodies market players, cancer monoclonal antibodies market segments and geographies, leading competitor revenues, profiles and market shares.
TBRC’s cancer monoclonal antibodies market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.
Here Is A List Of Similar Reports From The Business Research Company:
Interested To Know More About The Business Research Company?
The Business Research Company has published over 1000 industry reports, covering over 2500 market segments and 60 geographies. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. The reports are updated with a detailed analysis of the impact of COVID-19 on various markets.
Read More About Us At https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Follow us on Facebook: https://www.facebook.com/TheBusinessResearchCompany
Follow us on LinkedIn: https://in.linkedin.com/company/the-business-research-company
Follow us on Twitter: https://twitter.com/tbrc_info
Check out our Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found This Article Helpful? Share It On: